Delving into the Latest Updates on Centaurus Biopharma Co Ltd with Synapse

Overview

Basic Info

Introduction

Centaurus Biopharma Co., Ltd. is situated in the Hongshan High-Tech Industrial Park, Chifeng City, Inner Mongolia. The company aspires to distinguish itself with a diverse product portfolio, aspiring to become a distinguished holder of various pharmaceuticals. Its comprehensive strategy involves creating a CDMO service platform focusing on new pharmaceuticals. With an aim to construct a tiered product line-up that includes generic drugs, high-end generic pharmaceuticals, and innovative medications, Centaurus Biopharma is dedicated to evolving into a sustainable, platform-based modern pharmaceutical company. It strives to emerge as a leading enterprise in the field of chemical medicine and new drug development within the autonomous region.

Tags

Endocrinology and Metabolic Disease

Neoplasms

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	4
Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4

Top 5 Target	Count

JAK1 x JAK2 x ROCK1 x ROCK2	1
ALK x FAK x IGF-1R x PYK2	1

主要研究目的: 评价TQ05105片在不同级别肾功能受试者中单次给药后的药代动力学（PK）特征。次要研究目的：（1）评价TQ05105片在不同级别肾功能受试者中单次给药后的尿液中药物排泄情况。（2）评价TQ05105片在不同级别肾功能受试者中单次给药后的安全性。

[Translation]

Main study objectives: To evaluate the pharmacokinetic (PK) characteristics of TQ05105 tablets after a single dose in subjects with different levels of renal function. Secondary study objectives: (1) To evaluate the drug excretion in urine of TQ05105 tablets after a single dose in subjects with different levels of renal function. (2) To evaluate the safety of TQ05105 tablets after a single dose in subjects with different levels of renal function.

Start Date12 Oct 2024

Sponsor / Collaborator

Centaurus Biopharma Co Ltd

[+2]

CTR20240418 / CompletedNot Applicable

[14C] TQ05105在中国健康受试者体内的物质平衡临床试验

[Translation] [14C] TQ05105 clinical trial on material balance in healthy Chinese subjects

主要目的 1.定量分析健康受试者口服[14C]TQ05105后排泄物中的总放射性，获得人体放射性排泄率数据和主要排泄途径； 2.定量分析健康受试者单次口服[14C]TQ05105后全血和血浆中的总放射性，获得血浆中总放射性的药代动力学参数，并考察全血和血浆中总放射性的分配情况； 3.考察健康受试者口服[14C]TQ05105后人血浆、尿液和粪便的放射性物谱，鉴定主要代谢产物，确定主要生物转化途径及消除途径；次要目的 1.采用已验证的LC-MS/MS方法定量分析血浆中TQ05105及其代谢产物（TQ12550、TQ12581或更多）的浓度，获得血浆中TQ05105及其代谢产物（TQ12550、TQ12581或更多）的药代动力学参数； 2.观察[14C] TQ05105单次用药后健康受试者的安全性。

[Translation]

Main purpose 1. Quantitatively analyze the total radioactivity in excreta after oral administration of [14C]TQ05105 to healthy subjects, and obtain the data on human radioactive excretion rate and main excretion pathways; 2. Quantitatively analyze the total radioactivity in whole blood and plasma after a single oral administration of [14C]TQ05105 to healthy subjects, obtain the pharmacokinetic parameters of total radioactivity in plasma, and investigate the distribution of total radioactivity in whole blood and plasma; 3. Investigate the radioactivity spectrum of human plasma, urine and feces after oral administration of [14C]TQ05105 to healthy subjects, identify the main metabolites, and determine the main biotransformation pathways and elimination pathways; Secondary purpose 1. Quantitatively analyze the concentration of TQ05105 and its metabolites (TQ12550, TQ12581 or more) in plasma using a validated LC-MS/MS method, and obtain the pharmacokinetic parameters of TQ05105 and its metabolites (TQ12550, TQ12581 or more) in plasma; 2. Observe [14C] Safety of TQ05105 in healthy subjects after a single dose.

Start Date12 Mar 2024

Sponsor / Collaborator

Centaurus Biopharma Co Ltd

[+2]

CTR20232543 / CompletedPhase 1

评价TQ05105片药物-药物相互作用的I期临床试验

[Translation] Phase I clinical trial to evaluate drug-drug interactions of TQ05105 tablets

1、评价代谢酶抑制剂/诱导剂对TQ05105片体内代谢消除的影响； 2、评价代谢酶抑制剂/诱导剂与TQ05105片联合给药后的安全性。

[Translation]

1. Evaluate the effect of metabolic enzyme inhibitors/inducers on the metabolic elimination of TQ05105 tablets in vivo; 2. Evaluate the safety of combined administration of metabolic enzyme inhibitors/inducers and TQ05105 tablets.

Start Date19 Sep 2023

Sponsor / Collaborator

Centaurus Biopharma Co Ltd

[+2]

100 Clinical Results associated with Centaurus Biopharma Co Ltd

Login to view more data

0 Patents (Medical) associated with Centaurus Biopharma Co Ltd

Login to view more data

5

Literatures (Medical) associated with Centaurus Biopharma Co Ltd

15 Jul 2018·Cancer ResearchQ1 · MEDICINE

Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Q1 · MEDICINE

Article

Author: He, Qiaojun ; Yuan, Tao ; Ying, Meidan ; Zhu, Hong ; Fan, Guang-Han ; Chen, Ying ; Zeng, Chen-Ming ; Peng, Yong ; Cao, Ji ; Hu, Yuandong ; Chen, Zi-bo ; Wang, Dan-Dan ; Liu, Xi-Jie ; Yan, Fang-Jie ; Zhou, Tianyi ; Dai, Xiao-Yang ; Yang, Bo ; Luo, Peihua

AbstractGiven that Yes-associated protein (YAP) signaling acts as a critical survival input for hypoxic cancer cells in hepatocellular carcinoma (HCC), disruption of YAP function and the maintenance of hypoxia is an attractive way to treat HCC. Utilizing a cell-based YAP-TEAD luciferase reporter assay and functional analyses, we identified CT-707, a China-FDA approved multi-kinase inhibitor under clinical trial with remarkable inhibitory activity against YAP function. CT-707 exhibited prominent cytotoxicity under hypoxia on HCC cells, which was attributable to the inhibition of YAP signaling. CT-707 arrested tumor growth in HepG2, Bel-7402, and HCC patient-derived xenografts. Mechanistically, the inhibitory activity of CT-707 on YAP signaling was due to the interruption of hypoxia-activated IGF1R. Overall, these findings not only identify CT-707 as a promising hypoxia-targeting agent against HCC, but they also unveil IGF1R as a new modulator specifically regulating hypoxia-activated YAP signaling.Significance: CT-707 may represent a novel clinical approach for patients with HCC suffering poor drug response due to intratumor hypoxia. Cancer Res; 78(14); 3995–4006. ©2018 AACR.

01 May 2018·Journal of Pharmaceutical and Biomedical AnalysisQ3 · MEDICINE

An UPLC–MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients

Q3 · MEDICINE

Article

Author: Luo, Hong ; Zhao, Qian ; Kong, Fansheng ; Jiang, Ji ; Hu, Pei ; Cui, Cheng

CT-707, a mutant-selective inhibitor of an important cancer target, anaplastic lymphoma kinase (ALK), is designed to be a targeted therapeutic agent for non-small cell lung cancer (NSCLC) patients harboring ALK active and crizotinib resistant mutations. A rapid and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the determination of CT-707 and its two metabolites (M1 and M2) in human plasma. The samples were purified by solid phase extraction (SPE) and separated on a BEH C18 column (2.1 × 50 mm, 1.7 μm). Electrospray ionization (ESI) in positive ion mode and multiple reactions monitoring (MRM) were used to monitor the ion transitions at m/z 636.4⁺ → 413.3⁺, 594.4⁺ → 494.4⁺, 622.5⁺ → 536.4⁺, respectively. The results indicated that the method had excellent sensitivity and selectivity. The linear range covered from 2 to 500 ng/mL for CT-707and from 1 to 100 ng/mL for M1 and M2. Intra-run and inter-run precisions (in terms of %RSD) were all <15% and the accuracies (in terms of %RE) were within the range of ±15%. The lower limit of quantification (LLOQ), matrix effect, extraction recovery, stability, dilution test and carryover test were also validated and satisfied with the criteria of validation. Finally, the method was successfully applied to a phase I clinical study of ALK-positive advanced NSCLC patients after an oral administration of CT-707.

01 Jan 2017·Journal of CancerQ3 · MEDICINE

CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Q3 · MEDICINE

ArticleOA

Author: Hu, Yuandong ; Wu, Qiong ; Xiao, Dengming ; Sun, Ying ; Jing, Lutao ; Peng, Yong ; Liu, Qichao ; Tang, Guojing ; Zhao, Na ; Luo, Hong ; Sun, Yinghui ; Liu, Yuliang ; Wu, Mangang ; Han, Yongxin ; Han, Yunqi ; Wang, He ; Wang, Huan ; Sun, Deguang ; Kong, Fansheng

Kinase inhibitors that target Bcr-Abl are highly effective in the treatment of chronic myeloid leukemia (CML). However, these inhibitors are often invalidated due to the drug resistance. Therefore, the discovery and development of novel Bcr-Abl inhibitors is required to overwhelm the drug resistance in the treatment of CML resistant to the currently used first-line Bcr-Abl inhibitors. Herein we have described a newly developed Bcr-Abl inhibitor CT-721, which displayed potent inhibitory effects on wild-type and T315I mutant Bcr-Abl. It functioned as a typically ATP-competitive inhibitor, superior to other existing Bcr-Abl inhibitors. CT-721 also demonstrated time-dependent inhibition of Bcr-Abl activation and the resultant downstream signaling transduction pathways in Bcr-Abl positive cells. Furthermore, CT-721 induced cell apoptosis and cell cycle arrest, and efficaciously inhibited tumor growth in Bcr-Abl-expressed K562 and KU812 xenograft models in a mechanism-based manner. Further PK/PD studies revealed a positive in vivo correlation between the compound concentration and inhibition of Bcr-Abl activity. Taken together, CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor, and has shown strong in vitro and in vivo anti-CML activities with a favorable pharmacokinetic profile, differentiating it from other Bcr-Abl kinase inhibitors already approved and current in development for the treatment of CML.

100 Deals associated with Centaurus Biopharma Co Ltd

Login to view more data

100 Translational Medicine associated with Centaurus Biopharma Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 2 Clinical

Other

9

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Rovadicitinib ( JAK1 x JAK2 x ROCK1 x ROCK2 )	Myelofibrosis More	Phase 2
CT-1005	Diabetes Mellitus More	Preclinical
CT-1006	Diabetes Mellitus More	Preclinical
Conteltinib ( ALK x FAK x IGF-1R x PYK2 )	Hepatocellular Carcinoma More	Preclinical
TQB3456 ( EGFR )	Non-Small Cell Lung Cancer More	Pending